FilingIndex
← The Wire
LENZNasdaq

LENZ Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · DE · CIK 1815776

Develops and commercializes VIZZ, an eye drop to improve near vision for presbyopia

$212M
Market cap
$5.76
Last close
-1.0%
1D
-1.0%
5D
594K
Volume
Price · last 39 sessions-37.9%
May 4L $5.51 · H $10.06Jun 29
111
Total filings
Jun 12, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 12, 202610-Q10-QMay 11, 20268-KResults of OperationsMay 11, 2026DEFA14ADEFA14AApr 28, 2026DEF 14ADEF 14AApr 28, 202610-K10-KMar 24, 20268-KResults of OperationsMar 24, 20268-KResults of OperationsJan 7, 20268-KCompany UpdateDec 12, 202510-Q10-QNov 5, 20258-KResults of OperationsNov 5, 20258-KCompany UpdateOct 8, 20258-KReg FD Disclosure · Company UpdateSep 30, 20258-KCompany UpdateJul 31, 202510-Q10-QJul 30, 20258-KResults of OperationsJul 30, 20258-KShareholder VoteJun 10, 202510-Q10-QMay 7, 20258-KResults of OperationsMay 7, 2025DEFA14ADEFA14AApr 28, 2025DEF 14ADEF 14AApr 28, 20258-KResults of Operations · Reg FD DisclosureApr 15, 2025424B5424B5Apr 14, 20258-KMaterial AgreementApr 4, 202510-K10-KMar 19, 20258-KResults of OperationsMar 19, 202510-Q10-QNov 6, 20248-KResults of OperationsNov 6, 20248-KCompany UpdateOct 28, 2024S-1S-1Sep 11, 202410-Q10-QAug 14, 20248-KResults of OperationsAug 14, 20248-KCompany UpdateAug 12, 2024SC 13GSC 13GJul 29, 20248-KMaterial Agreement · Equity IssuanceJul 15, 202410-Q10-QMay 8, 20248-KResults of OperationsMay 8, 2024S-1/AS-1/AApr 9, 20248-KCompany UpdateApr 3, 2024S-1S-1Mar 29, 2024SC 13GLENZ THERAPEUTICS, INC.Mar 28, 2024SC 13DSC 13DMar 28, 2024SC 13GLENZ THERAPEUTICS, INC.Mar 25, 20248-KAuditor Change · Change of ControlMar 22, 20248-KReg FD DisclosureMar 19, 20248-KShareholder VoteMar 14, 2024425425Mar 8, 20248-KReg FD DisclosureMar 8, 2024425425Mar 5, 20248-KCompany UpdateMar 5, 202410-K10-KFeb 27, 2024SC 13GSC 13GFeb 5, 2024425425Dec 26, 20238-KCompany UpdateDec 26, 2023S-4S-4Dec 6, 2023425425Nov 15, 2023425425Nov 15, 20238-KChange of Control · Executive ChangeNov 15, 202310-Q10-QNov 13, 20238-KMaterial AgreementOct 30, 20238-K/AExecutive ChangeSep 13, 20238-KExecutive Change · Exit / Disposal CostsAug 23, 202310-Q10-QAug 14, 20238-KExecutive ChangeAug 2, 20238-KShareholder VoteJul 20, 20238-KExecutive Change · Reg FD DisclosureJun 23, 2023DEFA14ADEFA14AJun 6, 2023DEF 14ADEF 14AJun 6, 202310-Q10-QMay 11, 202310-K/A10-K/AApr 27, 202310-K10-KMar 20, 20238-KResults of OperationsMar 20, 20238-KExecutive ChangeMar 16, 20238-KExecutive Change · Exit / Disposal CostsFeb 22, 20238-KCompany UpdateJan 5, 20238-KCompany UpdateDec 12, 2022SC 13GSC 13GNov 18, 202210-Q10-QNov 9, 20228-KResults of OperationsNov 9, 20228-KCompany UpdateNov 3, 2022

Insider Activity

◆ Cluster Buy · 3 insiders

In the 90 days to Mar 27, 2026: 3 insiders bought $366K.

DateInsiderActionSharesPriceValue
Mar 27, 2026Schimmelpennink Evert B.President, CEO and SecretaryBuy28,089$8.95$251K
Mar 27, 2026Chevallard Daniel R.Chief Financial OfficerBuy7,500$8.57$64K
Mar 27, 2026George Jeffrey P.DirectorBuy5,592$8.92$50K
Nov 17, 2025Olsson ShawnChief Commercial OfficerSell5,788$26.37$153K
Nov 17, 2025Olsson ShawnChief Commercial OfficerSell4,212$25.74$108K
Nov 7, 2025Mccollum James WDirectorBuy10,500$22.79$239K
Nov 7, 2025Chevallard Daniel R.Chief Financial OfficerBuy2,178$22.76$50K
Nov 7, 2025Chevallard Daniel R.Chief Financial OfficerBuy20$22.71$454
Sep 30, 2025Versant Vantage Ii Gp-Gp, LlcTenPercentOwnerSell83,066$46.41$3.9M
Sep 30, 2025Versant Vantage Ii Gp-Gp, LlcTenPercentOwnerSell57,502$46.41$2.7M
Sep 30, 2025Versant Vantage Ii Gp-Gp, LlcTenPercentOwnerSell49,701$45.35$2.3M
Sep 30, 2025Versant Vantage Ii Gp-Gp, LlcTenPercentOwnerSell34,405$45.35$1.6M
Sep 30, 2025Versant Vantage Ii Gp-Gp, LlcTenPercentOwnerSell177$47.01$8K
Sep 30, 2025Versant Vantage Ii Gp-Gp, LlcTenPercentOwnerSell123$47.01$6K

Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.

Similar companies

Comparable business profile · signals at a glance